Worldquant Millennium Advisors LLC reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 32.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 107,482 shares of the company's stock after selling 51,003 shares during the period. Worldquant Millennium Advisors LLC owned approximately 0.11% of Neurocrine Biosciences worth $12,384,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. CWM LLC lifted its stake in Neurocrine Biosciences by 46.8% during the second quarter. CWM LLC now owns 6,849 shares of the company's stock worth $943,000 after purchasing an additional 2,185 shares in the last quarter. QRG Capital Management Inc. lifted its stake in Neurocrine Biosciences by 11.5% during the 2nd quarter. QRG Capital Management Inc. now owns 17,710 shares of the company's stock worth $2,438,000 after acquiring an additional 1,832 shares in the last quarter. SG Americas Securities LLC purchased a new position in Neurocrine Biosciences during the 2nd quarter valued at about $5,848,000. Sequoia Financial Advisors LLC acquired a new position in Neurocrine Biosciences in the 2nd quarter valued at about $207,000. Finally, Wealth Enhancement Advisory Services LLC increased its stake in Neurocrine Biosciences by 34.0% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 6,357 shares of the company's stock worth $875,000 after purchasing an additional 1,613 shares during the period. Institutional investors and hedge funds own 92.59% of the company's stock.
Neurocrine Biosciences Price Performance
Shares of NBIX traded up $1.72 during midday trading on Friday, reaching $128.14. 547,973 shares of the stock were exchanged, compared to its average volume of 907,006. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98. The company has a market capitalization of $12.97 billion, a price-to-earnings ratio of 34.35 and a beta of 0.34. The business's 50-day moving average price is $120.33 and its 200 day moving average price is $131.03.
Analyst Upgrades and Downgrades
NBIX has been the subject of several recent research reports. BMO Capital Markets lowered their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating for the company in a research note on Thursday, October 17th. Cantor Fitzgerald reissued an "overweight" rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Barclays cut their price objective on Neurocrine Biosciences from $180.00 to $160.00 and set an "overweight" rating on the stock in a research report on Monday, September 9th. Royal Bank of Canada reduced their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating on the stock in a research note on Friday, October 4th. Finally, Raymond James reissued an "outperform" rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Five investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences has a consensus rating of "Moderate Buy" and an average target price of $163.91.
Read Our Latest Research Report on NBIX
Insider Buying and Selling
In related news, insider Jude Onyia sold 2,331 shares of the company's stock in a transaction on Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the sale, the insider now owns 15,449 shares in the company, valued at $1,951,054.21. This represents a 13.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is currently owned by company insiders.
Neurocrine Biosciences Company Profile
(
Free Report)
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Featured Articles
Before you consider Neurocrine Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.
While Neurocrine Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
